Influ's treatment drug “Avigan” Clinical trial of new corona treatment started April 1 at 0:12
A Japanese pharmaceutical company that manufactures a novel influenza drug, Avigan, has announced that it has begun clinical trials to receive national approval for the treatment of the new coronavirus.
Avigan and Fabipiravir, a generic name, were developed by a pharmaceutical company, Fujifilm Toyama Chemical, six years ago as a treatment for a new type of influenza. Announced.
The clinical trials will be conducted until about the end of June in approximately 100 patients infected with the new coronavirus at a hospital in Tokyo until the end of June to confirm the efficacy and safety of the treatment.
Avigan has been reported in animal studies as having side effects on the fetus, so it cannot be administered to pregnant women, and if an infectious disease that does not work with other drugs occurs and the government decides to use it, Is to be administered.
In China, a clinical study of administration to patients infected with the new coronavirus has already been reported to be effective in improving symptoms such as pneumonia.
In Japan, clinical research to determine whether it is effective against the new coronavirus has begun in March at Fujita Medical University Hospital in Aichi Prefecture.
FUJIFILM Toyama Chemical plans to submit an application for approval of a new type of coronavirus to the government if its efficacy and safety are confirmed as a result of clinical trials.